Abstract
Vascular targeting agents (VTA) are designed to bind selectively to components of tumor vasculature and deliver an effector molecule that, directly or indirectly, causes occlusion of the tumor vessels. Blood flow to the tumor thus ceases, resulting in tumor cell death due to the cells’ inability to obtain oxygen and nutrients (Fig. 1, below). This approach has several advantages. Firstly, the tumor endothelial cells are directly accessible to intravenously administrated therapeutic agents, permitting rapid localization of a high percentage of the injected dose. Secondly, since each capillary provides oxygen and nutrients for thousands of tumor cells, occlusion of the vessel has an amplified effect on tumor cells. Thirdly, the outgrowth of mutant endothelial cells lacking the target antigen is unlikely because they comprise a normal, genetically stable cell population. Finally, since tumor vessels share common morphological and biochemical properties, this strategy should be applicable to different tumor types.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Folkman, J. and Shing, Y. Angiogenesis. J.Biol.Chem., 267: 10931–10934, 1992.
Hillen, H. F. Thrombosis in cancer patients. Ann.of Oncol., 11 (SUPPL 3): 273–276, 2000.
Wilcox, J. N., Smith, K. M., Schwartz, S. M., and Gordon, D. Localization of tissue factor in the normal vessel wall and in the atherosclerotic plaque. Proc.Natl.Acad.Sci.USA, 86: 2839–2843, 1989.
Ruf, W., Rehemtulla, A., and Edgington, T. S. Phospholipid-independent and–dependent interactions required for tissue factor receptor and cofactor function. J.Biol.Chem., 266: 2158–2166, 1991.
Huang, X., Molema, G., King, S., Watkins, L., Edgington, T. S., and Thorpe, P. E. Tumor infarction in mice by antibody-directed targeting of tissue factor to tumor vasculature. Science, 275: 547–550, 1997.
Ruco, L. P., Pomponi, D., Pigott, R., Stoppacciaro, A., Monardo, F., Uccini, S., Boaraschi, D., Tagliabue, A., Santoni, A., Dejana, E., Mantovani, A., and Baroni, C. D. Cytokine production (IL-a alpha, IL-1 beta, and TNF alpha) and endothelial cell activation (ELAM-1 and HLA-DR) in reactive lymphadenitis, hodgkin’s disease, and in non-hodgkin’s lymphomas. Am. J Pathol., 137(5): 1163–1171, 1990.
Ran, S., Gao, B., Duffy, S., Watkins, L., Rote, N. S., and Thorpe, P. E. Infarction of solid Hodgkin’s tumors in mice by antibody-directed targeting of tissue factor to tumor vasculature. Cancer Res, 58(20): 4646–4653, 1998.
Viti, F., Tarli, L., Giovannoni, L., Zardi, L., and Neri, D. Increased binding affinity and valence of recombinant antibody fragments lead to improved targeting of tumoral angiogenesis. Cancer Res, 59: 347–352, 1999.
Nilsson, F., Kosmehl, H., Zardi, L., and Neri, D. Targeted delivery of tissue factor to the ED-B domain of fibronectin, a marker of angiogenesis, mediates the infarction of solid tumors in mice. Cancer Res, 61(2): 711–716, 2001.
Williamson, P. and Schlegel, R. A. Back and forth: the regulation and function of transbilayer phospholipid movement in eukaryotic cells. Molec.Mem.Biol., 11: 199216, 1994.
Camemolla, B., Balza, E., Siri, A., Zardi, L., Nicotra, M. R., Bigotti, A., and Natali, P. G. A tumor-associated fibronectin isoform generated by alternative splicing of messenger RNA precursors. J.Cell Biol., 108: 1139–1148, 1989.
Karelina, TV. and Eisen, A. Z. Interstitial collagenase and the ED-B oncofetal domain of fibronectin are markers of angiogenesis in human skin tumors. Cancer Detect.Prev., 22(5): 438–444, 1998.
Israeli, R. S., Powell, C. T., Fair, W. R., and Heston, W. D. W. Molecular cloning of a complementary DNA encoding a prostate-specific membrane antigen. Cancer Res, 53: 227–230, 1993.
Silver, D. A., Pellicer, I., Fair, W. R., Heston, W. D. W., and Cordon-Cardo, C. Prostate-specific membrane antigen expression in normal and malignant human tissues. Clin.Cancer Res., 3: 81–85, 1997.
Shweiki, D., Itin, A., Neufeld, G., Gitay-Goren, H., and Keshet, E. Patterns of expression of vascular endothelial growth factor (VEGF) and VEGF receptors in mice suggest a role in hormonally regulated angiogenesis. J.Clin.Invest., 91: 2235–2243, 1993.
Dvorak, H. F., Sioussat, T. M., Brown, L. F., Berse, B., Nagy, J. A., Sotrel, A., Manseau, E. J., Vandewater, L., and Senger, D. R. Distribution of vascular permeability factor (vascular endothelial growth factor) in tumors–concentration in tumor blood vessels. J.Exp.Med., 174: 1275–1278, 1991.
Brekken, R. A., Overholser, J., Stastny, V. A., Waltenberger, J., Minna, J., and Thorpe, P. E. Selective inhibition of vascular endothelial growth factor (VEGF) receptor2 (KDR/Flk-1) activity by a monoclonal anti-VEGF antibody blocks tumor growth in mice. Cancer Res, 60: 5117–5124, 2000.
Cooke, S. P., Boxer, G. M., Lawrence, L., Pedley, R. B., Spencer, D. I. R., Begent, R. H. J., and Chester, K. A. A strategy for antitumor vascular therapy by targeting the vascular endothelial growth factor:receptor complex. Cancer Res, 61: 3653–3659, 2001.
Ramakrishnan, S., Olson, T. A., Bautch, V. L., and Mohanraj, D. Vascular endothelial growth factor-toxin conjugate specifically inhibits KDR/flk-l-positive endothelial cell proliferation in vitro and angiogenesis in vivo. Cancer Res., 56: 1324–1330, 1996.
Fonsatti, E., Del Vecchio, L., Altomonte, M., Sigalotti, L., Nicotra, M. R., Coral, S., Natali, P. G., and Maio, M. Endoglin: an accessory component of the TGF-E-binding receptor-complex with diagnostic, prognostic, and bioimmunotherapeutic potential in human malignancies. J.Cell.Physiol., 188: 1–7, 2001.
Burrows, F. J., Derbyshire, E. J., Tazzari, P. L., Amlot, P., Gazdar, A. F., King, S. W., Letarte, M., Vitetta, E. S., and Thorpe, P. E. Endoglin is an endothelial cell proliferation marker that is upregulated in tumor vasculature. Clin.Cancer Res., 1: 1623–1634, 1995.
Seon, B. K., Matsuno, F., Haruta, Y., Kondo, M., and Barcos, M. Long-lasting complete inhibition of human solid tumors in SCID mice by targeting endothelial cells of tumor vasculature with antihuman endoglin immunotoxin. Clin.Cancer Res., 3: 1031–1044, 1997.
Rettig, W. J., Garinchesa, P., Healey, J. H., Su, S. L., Jaffe, E. A., and Old, L. J. Identification of endosialin, a cell surface glycoprotein of vascular endothelial cells in human cancer. Proc Natl.Acad.Sci.USA, 89: 10832–10836, 1992.
Carson-Walter, E. B., Watkins, D. N., Nanda, A., Vogelstein, B., Kinzler, K. W., and St.Croix, B. Cell surface tumor endothelial markers are conserved in mice and humans. Cancer Res, 61(18): 6649–6655, 2001.
Christian, S., Ahorn, H., Koehler, A., Eisenhaber, F., Rodi, H. P., Garin-Chesa, P., Park, J. E., Rettig, W. J., and Lenter, M. C. Molecular cloning and characterization of endosialin, a C-type lectin-like cell surface receptor of tumor endothelium. J Biol.Chem, 276(10): 7408–7414, 2001.
Brooks, P. C., Clark, R. A., and Cheresh, D. A. Requirement of vascular integrin alpha v beta 3 for angiogenesis. Science, 264: 569–571, 1994.
Brooks, P. C., Montgomery, A. M. P., Rosenfeld, M., Reisfeld, R. A., Hu, T., Klier, G., and Cheresh, D. A. Integrin alpha v beta 3 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels. Cell, 79: 1157–1164, 1994.
Pasqualini, R., Koivunen, E., and Ruoslahti, E. Alpha v integrins as receptors for tumor targeting by circulating ligands. Nature Biotechnology, 15(6): 542–546, 1997.
Lode, H. N., Moehler, T., Xiang, R., Jonczyk, A., Gillies, S. D., Cheresh, D. A., and Reisfeld, R. A. Synergy between an antiangiogenic integrin alpha V antagonist and an antibody-cytokine fusion protein eradicates spontaneous tumor metastases. Proc.Natl.Acad.Sci.(USA), 96(4): 1591–1596, 1999.
Arap, W., Pasqualini, R., and Ruoslahti, E. Cancer treatment by targeted drug delivery to tumor vasculature in a mouse model. Science, 279: 377–380, 1998.
Ohizumi, I., Tsunoda, S., Taniguchi, K., Saito, H., Esaki, K., Koizumi, K., Makimoto, H., Wakai, Y., Matsui, J., Tsutsumi, Y., Nakagawa, S., Utoguchi, N., Ohsugi, Y., and Mayumi, T. Identification of tumor vascular antigens by monoclonal antibodies prepared from rat-tumor-derived endothelial cells. Int J Cancer, 77(4): 561–566, 1998.
Jacobson, B. S., Stolz, D. B., and Schnitzer, J. E. Identification of endothelial cell-surface proteins as targets for diagnosis and treatment of disease. Nature Med., 2: 482–484, 1996.
St.Croix, B., Rago, C., Velculescu, V., Traverso, G., Romans, K. E., Montgomery, E., Lal, A., Riggins, G. J., Lengauer, C., Vogelstein, B., and Kinzler, K. W. Genes expressed in human tumor endothelium. Science, 289(5482): 1197–1202, 2000.
Pasqualini, R. and Ruoslahti, E. Organ targeting in vivo using phage display peptide libraries. Nature, 380: 364–366, 1996.
Ruoslahti, E. Targeting tumor vasculature with homing peptides from phage display. Semin Cancer Biol, 10(6): 435–442, 2000.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2002 Springer Science+Business Media New York
About this chapter
Cite this chapter
Ran, S., Rosenblum, M., Thorpe, P.E. (2002). Ligand-Directed Destruction of Tumor Vasculature. In: Muzykantov, V., Torchilin, V. (eds) Biomedical Aspects of Drug Targeting. Springer, Boston, MA. https://doi.org/10.1007/978-1-4757-4627-3_12
Download citation
DOI: https://doi.org/10.1007/978-1-4757-4627-3_12
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4419-5312-4
Online ISBN: 978-1-4757-4627-3
eBook Packages: Springer Book Archive